It was our lab’s earlier research that demonstrated the anti-addiction properties of a nutraceutical containing amino acids precursors and enkephalinase inhibitors, as well as the discovery of the first polymorphic gene associated with severe alcoholism (DRD2) that laid the foundation for “Personalized Medicine.” Our BRC concept has long been used to stratify addiction risk through neurogenetics, even before the later genetic finding. Here, DRD2 is linked to alcohol drinking.